Room 6007, Level 6, Pharmacy Australia Centre of Excellence
Phone: +61 7-334-61855; Fax: +61 7-334-61999

Research Interests

Greg’s research team at UQ seeks to identify and characterise novel therapeutic targets for the treatment of cancer. A particular focus of his research group is the identification of new drug targets for breast cancer subtypes for which there are few effective therapies and the prognosis is poor.

Image of Monteith Lab Group
Calcium Signaling in Cancer Research Laboratory 2016 Research Retreat
Greg uses a variety of approaches to identify calcium channels and pumps that may be targets for cancer drug development. His research team consists of PhD students and post-doctoral researchers from a diverse array of backgrounds including Pharmacy, Biotechnology, Biochemistry, Chemistry, Microbiology and Pharmacology. Members of his group are studying specific calcium pumps and channels as new drug targets, calcium signaling pathways in cancer cells and new approaches in biomolecular high throughput screening. 

PhD students and post-doctoral researchers who join his research group will be trained in methods to image calcium signaling in living cells, molecular pharmacology techniques and pharmaceutical industry relevant bioassays for drug discovery.

Training in his laboratory is well suited for students and early career researchers considering careers in biomedical research and/or pharmaceutical industry drug discovery programs.The group’s work is published in leading scientific journals including Nature Reviews Cancer, Journal of Biology Chemistry and Trends in Pharmacological Sciences.

His laboratory has received over $ 7 million dollars in research funding, and is currently supported by the National Health and Medical Research Council of Australia, Australian Research Council and the Cancer Council of Queensland.

Dr Helen Faddy
Our high throughput calcium signaling instrument (FLIPR) used for drug target identification and characterisation studies as well as biomolecular screening

Greg has advised over 20 PhD students. Alumni from his group include holders of prestigious NHMRC postdoctoral fellowships and those with careers in research commercialisation. In 2006, Greg received the UQ Foundation research excellence award, in recognition of his contribution to calcium signaling research in cancer.

 Selected Publications

  • Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 35:479-88, 2014.
  •  Azimi I, Roberts-Thomson SJ, Monteith GR. Calcium influx pathways in breast cancer: opportunities for pharmacological intervention. Br J Pharmacol. 171:945-60.,2014
  • Davis FM1, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW Jr, Goodhill GJ, Thompson EW, Roberts-Thomson SJ, Monteith GR. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. doi: 10.1038/onc.2013.187, 2013
  • Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, Roberts-Thomson SJ, Monteith GR. Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther.;11:2158-68, 2012
  • Feng M, Grice D, Faddy H, Nguyen N, Leitch S, Wang Y, Muend S, Kenny P, Sukumar S, Roberts-Thomson SJ, Monteith GR, Rao R. Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors. Cell. 143: 84-98. 2010
  • Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport. Nature Reviews Cancer. 7:519-30, 2007
  • Monteith GR and Bird St J. High throughput measurement of calcium: back to basics. Trends in Pharmacological Sciences 26(4):218-23, 2005



On this site